Introduction
A new opioid-like risk is sitting on the counter at gas stations, smoke shops, and vape shops. It is called 7-hydroxymitragynine, also known as 7-OH, 7-hydroxy, or 7-OHMG, and it is often sold under kratom branding. Treatment centers, emergency departments, poison control centers, and toxicology teams are all taking notice. The concern is not traditional kratom leaf. It is concentrated 7-OH, which can act as a potent opioid-like substance. For clinicians, the question is shifting from “Does this patient use kratom?” to “Is this patient using concentrated 7-OH?” Answering it takes better intake questions and the right toxicology testing. Acutis Diagnostics tests for 7-OH and kratom to help providers get that answer.
Only a handful of states regulate 7-OH sales, and legislation often lags behind new product formulations. Federal action is now catching up. The FDA recommended scheduling 7-OH in July 2025. In October 2026, the DEA announced its intent to temporarily place 7-OH above a set concentration threshold in Schedule I, the most restrictive category of controlled substances. The order can take effect on or after November 13, 2026, and would last two years, with a possible one-year extension, while permanent scheduling is completed.
What Is 7-OH?
7-OH is an alkaloid found in small amounts in the kratom plant, Mitragyna speciosa. The leaf’s main alkaloid, mitragynine, is partly converted into 7-OH by liver enzymes. Research suggests this conversion drives much of kratom’s opioid-like effect. On its own, 7-OH acts on the same mu-opioid receptors as morphine. The FDA has described it as an opioid that can be more potent than morphine. No 7-OH drug is FDA-approved, and it cannot be lawfully sold as a dietary supplement or food.
Is 7-OH the Same as Kratom?
No. Traditional kratom leaf contains only low levels of 7-OH. Concentrated products may contain enhanced, semi-synthetic, or synthetic 7-OH at levels far above anything found naturally in the leaf. That means two patients who both say “I use kratom” may have very different exposures. It is also why the “kratom is safe” versus “kratom is dangerous” debate is too broad. A more useful starting point: some kratom-branded products may expose users to concentrated 7-OH. This also answers a common question: is kratom an opioid? Kratom is a plant, not an opioid medicine. But its alkaloids act on opioid receptors, and concentrated 7-OH behaves far more like an opioid than the leaf does.
Where Is 7-OH Sold?
7-OH is not sold in pharmacies. Because there is no FDA-approved 7-OH medicine, pharmacies do not stock it. Instead, it is sold in smoke shops, vape shops, convenience stores, gas stations, and online. It often looks harmless. Products come as tablets, gummies, liquid shots, powders, drink mixes, extracts, vapes, and candy-like products. Packaging often resembles a supplement or candy, and many buyers do not know what they are actually taking. Patients may not call it 7-OH at all. Terms like “gas station kratom,” “7 tablets,” or “smoke-shop product” can all point to concentrated 7-OH.
What Is 7-OH Used For?
People report using 7-OH for pain relief, energy, mood, relaxation, and sleep. Some use it to self-treat anxiety, mood symptoms, or opioid withdrawal. None of these uses is approved, and product strength can vary widely from one package to the next.
This matters for treatment centers. A patient may see 7-OH as a “natural” aid for pain or withdrawal while it quietly sustains opioid-like dependence.
What Are the Reported Effects of 7-OH?
Reported effects of 7-OH exposure include nausea and vomiting, agitation or confusion, sweating, rapid heart rate, high blood pressure, breathing difficulty, sedation or loss of consciousness, seizures, and respiratory depression. Many of these overlap with opioid effects. That is why 7-OH can look like an opioid exposure in a patient who denies opioid use.
The challenge is recognizing these exposures early, especially when a patient describes their use as “kratom” or a “smoke-shop product.”
Are There Known Side Effects of 7-OH?
Yes. 7-OH has opioid-receptor activity and may be linked to dependence, withdrawal, respiratory depression, overdose-like toxicity, and severe adverse reactions. Respiratory depression is the most serious concern, especially when 7-OH is combined with alcohol, benzodiazepines, opioids, sedatives, antidepressants, or other substances. Polysubstance use is a major risk multiplier. In one study of impaired-driving cases involving kratom, every case also involved at least one other drug.
Does naloxone work on 7-OH? Naloxone may help reverse respiratory depression. Patients may still need monitoring, repeat dosing, and supportive care, so naloxone is one part of the response, not the whole response.
Can 7-OH Cause Dependence and Withdrawal?
Yes. 7-OH may cause dependence, and users may report tolerance, cravings, and rising doses over time. Clinicians may hear this described as kratom dependence, even when the real driver is concentrated 7-OH. When use stops, withdrawal can look much like opioid withdrawal: anxiety, restlessness, chills, diarrhea, abdominal cramps, nausea, vomiting, muscle aches, insomnia, sweating, fast heart rate, high blood pressure, and cravings. Intake teams should ask about 7-OH directly. One simple way to phrase it:
“Have you used any kratom products, 7-OH, 7-hydroxy, shots, gummies, extracts, smoke-shop tablets, or online products for pain, mood, energy, sleep, or withdrawal?”
Why Does 7-OH Often Go Unnoticed?
7-OH use is likely more common than current numbers show. Patients may not know a product contains 7-OH. Labels can be unclear, and products are often sold simply as “kratom.” Surveillance systems tend to group cases under kratom, and clinicians may not think to ask. There is also a testing gap, because routine drug screens may not detect 7-OH. If a team does not ask about 7-OH by name and test for it specifically, it can go unnoticed.
Does 7-OH Show Up on a Drug Test?
Not on a routine one. Standard opiate and opioid screens are built to detect drugs such as morphine, oxycodone, or fentanyl. 7-OH and mitragynine have a different chemical structure, so a patient can test negative on a routine panel while still using concentrated 7-OH. The same is true for kratom. A kratom drug test has to look for kratom alkaloids specifically, typically using liquid chromatography with tandem mass spectrometry (LC-MS/MS).
Can 7-OH Be Detected in Urine or Saliva?
Yes, with targeted testing. Each specimen type tells a slightly different story:
- Urine is the most established specimen for drug testing and already fits most treatment center workflows.
- Oral fluid (saliva) is collected under direct observation, which can reduce tampering. It tends to reflect more recent use.
- Blood is mainly used in emergency, hospital, and forensic settings.
At Acutis, 7-OH testing is currently offered in urine.
How Long Does 7-OH Stay in Your System?
Researchers do not know yet. Detection windows for 7-OH in urine and oral fluid have not been established. A 2026 study by Huestis and colleagues measured 7-OH in plasma, but published data for urine and oral fluid are still missing. Until that research arrives, detection should be expected to vary with dose, how often a person uses, product strength, metabolism, collection timing, and the laboratory’s cutoffs. That is another reason to read any 7-OH result alongside the patient’s history.
Making Sense of a 7-OH Result
A positive 7-OH result answers one question and raises a few others. Because the body makes some 7-OH from mitragynine, a 7-OH finding alone does not always prove use of a concentrated product. Reading 7-OH alongside mitragynine adds context.
| Laboratory pattern | What it may suggest |
| 7-OH and mitragynine both detected | Consistent with kratom use. 7-OH may come from the product, from the body’s conversion of mitragynine, or both. |
| 7-OH detected, mitragynine low or absent | May suggest use of a concentrated 7-OH product rather than traditional leaf. |
| Mitragynine detected, 7-OH not detected | Consistent with kratom use, with 7-OH below the reporting limit. |
| Routine opioid screen negative, opioid-like symptoms present | Routine screens are not designed for 7-OH. Targeted testing may help. |
These patterns are clinical signals, not proof. Results should be read alongside the patient’s history, symptoms, collection timing, and any other substances found. A single finding supports clinical judgment. It does not replace it.
Why Clinical Toxicology Testing Matters
Unexplained sedation, respiratory depression, seizure-like symptoms, withdrawal, or relapse in a patient who denies opioid use should prompt clinicians to consider 7-OH. Toxicology testing can clarify exposure when a patient’s history or a product’s label is unreliable. Testing can be useful at several points in care: intake, withdrawal management, relapse evaluation, overdose-risk review, MAT planning, counseling, and discharge planning.
“The onus is on laboratories to keep a pulse on what’s appearing on the street.”
Jibreel Sarij, CEO, Acutis Diagnostics
Does Acutis Test for 7-OH? Yes.
Acutis Diagnostics offers targeted 7-OH (kratom) testing so treatment centers and providers can identify exposures that routine screens miss. Testing is performed in urine using definitive LC-MS/MS methods, and results can be reviewed alongside the rest of a patient’s toxicology profile.
Ordering is simple. Providers can order a 7-OH drug test through electronic orders or paper requisitions, so it fits the workflow your team already uses.
Turnaround time: Results are typically available in 48 to 72 hours, the same as other drugs on the Acutis menu.
To add 7-OH to your testing panel, contact service@acutis.com.
What Treatment Centers Should Do Now
- Update intake questions. Ask specifically about 7-OH, 7-hydroxy, kratom shots, gummies, and smoke-shop tablets.
- Train clinical staff. Make sure the team knows that “kratom use” may mean concentrated 7-OH exposure.
- Watch for opioid-like signs. Sedation, respiratory depression, withdrawal, seizures, or relapse should prompt deeper questions.
- Use toxicology strategically. When history and routine screens do not match, add targeted 7-OH testing.
The Bottom Line
7-OH is an emerging opioid-like exposure hiding behind kratom, wellness, pain relief, and “natural” language. Its risk is easy to underestimate because of how it is sold. Treatment centers can respond by asking better questions, recognizing opioid-like toxicity, preparing for withdrawal and overdose risk, and educating patients early. The warning signs are already visible. With 7-OH testing from Acutis, providers do not have to rely on patient history alone.
Key takeaway
Routine drug screens are not designed to detect 7-OH. Targeted testing can identify it in patients who report “kratom” use or show opioid-like symptoms with a negative opioid screen. Acutis offers 7-OH (kratom) testing through electronic and paper ordering.
About Acutis Diagnostics
Acutis Diagnostics provides comprehensive clinical toxicology solutions for treatment centers and healthcare providers supporting patients with substance use disorders. Our testing helps clinicians see emerging substances like 7-OH and make informed care decisions.
To learn more about 7-OH testing, contact service@acutis.com
References
- U.S. Food and Drug Administration. FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers. Press release, July 29, 2025.
- U.S. Food and Drug Administration. Hiding in Plain Sight: 7-OH Products.
- Drug Enforcement Administration. Schedules of Controlled Substances: Temporary Placement of 7-Hydroxymitragynine and Mitragynine Pseudoindoxyl Above a Specified Threshold in Schedule I. Federal Register, October 14, 2026.
- Kruegel AC, Uprety R, Grinnell SG, et al. 7-Hydroxymitragynine Is an Active Metabolite of Mitragynine and a Key Mediator of Its Analgesic Effects. ACS Central Science. 2019;5(6):992-1001.
- Kedzierski N, Mata D. Mitragynine in the Orange County DUID Population. Journal of Analytical Toxicology. 2023;47(8):770-785.
